Search

Your search keyword '"Desvaux, Emiko"' showing total 21 results
Start Over Author "Desvaux, Emiko"
21 results on '"Desvaux, Emiko"'

1. Consensus gene modules strategy identifies candidate blood-based biomarkers for primary Sjögren's disease

Author

Boudjeniba, Cheïma, Soret, Perrine, Trutschel, Diana, Hamon, Antoine, Baloche, Valentin, Chassagnol, Bastien, Desvaux, Emiko, Bichat, Antoine, Aussy, Audrey, Moingeon, Philippe, Lefebvre, Céline, Hubert, Sandra, Alarcon-Riquelmé, Marta, Ng, Wan-Fai, Gottenberg, Jacques-Eric, Schwikowski, Benno, Bombardieri, Michele, van Roon, Joel A.G., Mariette, Xavier, Guedj, Mickaël, Birmele, Etienne, Laigle, Laurence, and Becht, Etienne

Published
2024
Full Text
View/download PDF

2. Antibody-mediated neutralization of galectin-3 as a strategy for the treatment of systemic sclerosis

Author

Ortega-Ferreira, Céline, Soret, Perrine, Robin, Gautier, Speca, Silvia, Hubert, Sandra, Le Gall, Marianne, Desvaux, Emiko, Jendoubi, Manel, Saint-Paul, Julie, Chadli, Loubna, Chomel, Agnès, Berger, Sylvie, Nony, Emmanuel, Neau, Béatrice, Fould, Benjamin, Licznar, Anne, Levasseur, Franck, Guerrier, Thomas, Elouej, Sahar, Courtade-Gaïani, Sophie, Provost, Nicolas, Nguyen, The Quyen, Verdier, Julien, Launay, David, and De Ceuninck, Frédéric

Published
2023
Full Text
View/download PDF

6. Consensus gene modules strategy identifies candidate blood-based biomarkers for primary Sjögren's disease

Author

Lab Reumatologie/Klinische Immunologie, Infection & Immunity, MS Reumatologie/Immunologie/Infectie, Boudjeniba, Cheïma, Soret, Perrine, Trutschel, Diana, Hamon, Antoine, Baloche, Valentin, Chassagnol, Bastien, Desvaux, Emiko, Bichat, Antoine, Aussy, Audrey, Moingeon, Philippe, Lefebvre, Céline, Hubert, Sandra, Alarcon-Riquelmé, Marta, Ng, Wan Fai, Gottenberg, Jacques Eric, Schwikowski, Benno, Bombardieri, Michele, van Roon, Joel A.G., Mariette, Xavier, Guedj, Mickaël, Birmele, Etienne, Laigle, Laurence, Becht, Etienne, Lab Reumatologie/Klinische Immunologie, Infection & Immunity, MS Reumatologie/Immunologie/Infectie, Boudjeniba, Cheïma, Soret, Perrine, Trutschel, Diana, Hamon, Antoine, Baloche, Valentin, Chassagnol, Bastien, Desvaux, Emiko, Bichat, Antoine, Aussy, Audrey, Moingeon, Philippe, Lefebvre, Céline, Hubert, Sandra, Alarcon-Riquelmé, Marta, Ng, Wan Fai, Gottenberg, Jacques Eric, Schwikowski, Benno, Bombardieri, Michele, van Roon, Joel A.G., Mariette, Xavier, Guedj, Mickaël, Birmele, Etienne, Laigle, Laurence, and Becht, Etienne

Published
2024

7. A new molecular classification to drive precision treatment strategies in primary Sjögren’s syndrome

Author

Soret, Perrine, Le Dantec, Christelle, Desvaux, Emiko, Foulquier, Nathan, Chassagnol, Bastien, Hubert, Sandra, Jamin, Christophe, Barturen, Guillermo, Desachy, Guillaume, Devauchelle-Pensec, Valérie, Boudjeniba, Cheïma, Cornec, Divi, Saraux, Alain, Jousse-Joulin, Sandrine, Barbarroja, Nuria, Rodríguez-Pintó, Ignasi, De Langhe, Ellen, Beretta, Lorenzo, Chizzolini, Carlo, Kovács, László, Witte, Torsten, Bettacchioli, Eléonore, Buttgereit, Anne, Makowska, Zuzanna, Lesche, Ralf, Borghi, Maria Orietta, Martin, Javier, Courtade-Gaiani, Sophie, Xuereb, Laura, Guedj, Mickaël, Moingeon, Philippe, Alarcón-Riquelme, Marta E., Laigle, Laurence, and Pers, Jacques-Olivier

Published
2021
Full Text
View/download PDF

9. Industrializing AI-powered drug discovery: lessons learned from the Patrimony computing platform

Author

Guedj, Mickaël, primary, Swindle, Jack, additional, Hamon, Antoine, additional, Hubert, Sandra, additional, Desvaux, Emiko, additional, Laplume, Jessica, additional, Xuereb, Laura, additional, Lefebvre, Céline, additional, Haudry, Yannick, additional, Gabarroca, Christine, additional, Aussy, Audrey, additional, Laigle, Laurence, additional, Dupin-Roger, Isabelle, additional, and Moingeon, Philippe, additional

Published
2022
Full Text
View/download PDF

11. Syndrome de Gougerot-Sjögren: Vers une médecine de précision

Author

Laigle, Laurence, Le Dantec, Christelle, Soret, Perrine, Desvaux, Emiko, Hubert, Sandra, Foulquier, Nathan, Moingeon, Philippe, Guedj, Mickaël, Pers, Jacques-Olivier, Institut de Recherches Internationales Servier [Suresnes] (IRIS), Lymphocytes B, Autoimmunité et Immunothérapies (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-LabEX IGO Immunothérapie Grand Ouest, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Laboratoire Servier, Statistics In System biology and Translational Medicine (SISTM), Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)- Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Bordeaux (UB), Service de Médecine Gériatrique [CHU Limoges], CHU Limoges, CHU Pontchaillou [Rennes], Chambre de commerce et d’industrie - Paris-Île de France (CCIP IDF), ANR-11-LABX-0016,IGO,Immunothérapies Grand Ouest(2011), European Project: 115565,EC:FP7:SP1-JTI,IMI-JU-08-2012,PRECISESADS(2014), Sciences, EDP, Laboratoires d'excellence - Immunothérapies Grand Ouest - - IGO2011 - ANR-11-LABX-0016 - LABX - VALID, and Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases - PRECISESADS - - EC:FP7:SP1-JTI2014-02-01 - 2019-01-31 - 115565 - VALID

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience; No abstract available

Published
2022

13. Network-based repurposing identifies anti-alarmins as drug candidates to control severe lung inflammation in COVID-19

Author

Desvaux, Emiko, primary, Hamon, Antoine, additional, Hubert, Sandra, additional, Boudjeniba, Cheïma, additional, Chassagnol, Bastien, additional, Swindle, Jack, additional, Aussy, Audrey, additional, Laigle, Laurence, additional, Laplume, Jessica, additional, Soret, Perrine, additional, Jean-François, Pierre, additional, Dupin-Roger, Isabelle, additional, Guedj, Mickaël, additional, and Moingeon, Philippe, additional

Published
2021
Full Text
View/download PDF

14. A new molecular classification to drive precision treatment strategies in primary Sjögren's syndrome.

Author

UCL - SSS/IREC/FATH - Pôle de Pharmacologie et thérapeutique, UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Soret, Perrine, Le Dantec, Christelle, Desvaux, Emiko, Foulquier, Nathan, Chassagnol, Bastien, Hubert, Sandra, Jamin, Christophe, Barturen, Guillermo, Desachy, Guillaume, Devauchelle-Pensec, Valérie, Boudjeniba, Cheïma, Cornec, Divi, Saraux, Alain, Jousse-Joulin, Sandrine, Barbarroja, Nuria, Rodríguez-Pintó, Ignasi, De Langhe, Ellen, Beretta, Lorenzo, Chizzolini, Carlo, Kovács, László, Witte, Torsten, PRECISESADS Clinical Consortium, PRECISESADS Flow Cytometry Consortium, Bettacchioli, Eléonore, Buttgereit, Anne, Makowska, Zuzanna, Lesche, Ralf, Borghi, Maria Orietta, Martin, Javier, Courtade-Gaiani, Sophie, Xuereb, Laura, Guedj, Mickaël, Moingeon, Philippe, Alarcón-Riquelme, Marta E, Laigle, Laurence, Pers, Jacques-Olivier, Lauwerys, Bernard, Ducreux, Julie, Maudoux, Anne-Lise, UCL - SSS/IREC/FATH - Pôle de Pharmacologie et thérapeutique, UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Soret, Perrine, Le Dantec, Christelle, Desvaux, Emiko, Foulquier, Nathan, Chassagnol, Bastien, Hubert, Sandra, Jamin, Christophe, Barturen, Guillermo, Desachy, Guillaume, Devauchelle-Pensec, Valérie, Boudjeniba, Cheïma, Cornec, Divi, Saraux, Alain, Jousse-Joulin, Sandrine, Barbarroja, Nuria, Rodríguez-Pintó, Ignasi, De Langhe, Ellen, Beretta, Lorenzo, Chizzolini, Carlo, Kovács, László, Witte, Torsten, PRECISESADS Clinical Consortium, PRECISESADS Flow Cytometry Consortium, Bettacchioli, Eléonore, Buttgereit, Anne, Makowska, Zuzanna, Lesche, Ralf, Borghi, Maria Orietta, Martin, Javier, Courtade-Gaiani, Sophie, Xuereb, Laura, Guedj, Mickaël, Moingeon, Philippe, Alarcón-Riquelme, Marta E, Laigle, Laurence, Pers, Jacques-Olivier, Lauwerys, Bernard, Ducreux, Julie, and Maudoux, Anne-Lise

Abstract

There is currently no approved treatment for primary Sjögren's syndrome, a disease that primarily affects adult women. The difficulty in developing effective therapies is -in part- because of the heterogeneity in the clinical manifestation and pathophysiology of the disease. Finding common molecular signatures among patient subgroups could improve our understanding of disease etiology, and facilitate the development of targeted therapeutics. Here, we report, in a cross-sectional cohort, a molecular classification scheme for Sjögren's syndrome patients based on the multi-omic profiling of whole blood samples from a European cohort of over 300 patients, and a similar number of age and gender-matched healthy volunteers. Using transcriptomic, genomic, epigenetic, cytokine expression and flow cytometry data, combined with clinical parameters, we identify four groups of patients with distinct patterns of immune dysregulation. The biomarkers we identify can be used by machine learning classifiers to sort future patients into subgroups, allowing the re-evaluation of response to treatments in clinical trials.

Published
2021

15. S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN-α) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases

Author

Duguet, Fanny, primary, Ortega-Ferreira, Céline, additional, Fould, Benjamin, additional, Darville, Hélène, additional, Berger, Sylvie, additional, Chomel, Agnès, additional, Leclerc, Grégory, additional, Kisand, Kai, additional, Haljasmägi, Liis, additional, Hayday, Adrian C., additional, Desvaux, Emiko, additional, Nony, Emmanuel, additional, Moingeon, Philippe, additional, and De Ceuninck, Frédéric, additional

Published
2021
Full Text
View/download PDF

16. Model-based computational precision medicine to develop combination therapies for autoimmune diseases.

Author

Desvaux, Emiko, Aussy, Audrey, Hubert, Sandra, Keime-Guibert, Florence, Blesius, Alexia, Soret, Perrine, Guedj, Mickaël, Pers, Jacques-Olivier, Laigle, Laurence, and Moingeon, Philippe

Subjects
INDIVIDUALIZED medicine, AUTOIMMUNE diseases, T cells, LYMPHOCYTE transformation, ARTIFICIAL intelligence, B cells
Abstract

The complex pathophysiology of autoimmune diseases (AIDs) is being progressively deciphered, providing evidence for a multiplicity of pro-inflammatory pathways underlying heterogeneous clinical phenotypes and disease evolution. Treatment strategies involving drug combinations are emerging as a preferred option to achieve remission in a vast majority of patients affected by systemic AIDs. The design of appropriate drug combinations can benefit from AID modeling following a comprehensive multi-omics molecular profiling of patients combined with Artificial Intelligence (AI)-powered computational analyses. Such disease models support patient stratification in homogeneous subgroups, shed light on dysregulated pro-inflammatory pathways and yield hypotheses regarding potential therapeutic targets and candidate biomarkers to stratify and monitor patients during treatment. AID models inform the rational design of combination therapies interfering with independent pro-inflammatory pathways related to either one of five prominent immune compartments contributing to the pathophysiology of AIDs, i.e. pro-inflammatory signals originating from tissues, innate immune mechanisms, T lymphocyte activation, autoantibodies and B cell activation, as well as soluble mediators involved in immune cross-talk. The optimal management of AIDs in the future will rely upon rationally designed combination therapies, as a modality of a model-based Computational Precision Medicine taking into account the patients' biological and clinical specificities. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

17. Industrializing AI-powered drug discovery: lessons learned from the Patrimonycomputing platform

Author

Guedj, Mickaël, Swindle, Jack, Hamon, Antoine, Hubert, Sandra, Desvaux, Emiko, Laplume, Jessica, Xuereb, Laura, Lefebvre, Céline, Haudry, Yannick, Gabarroca, Christine, Aussy, Audrey, Laigle, Laurence, Dupin-Roger, Isabelle, and Moingeon, Philippe

Abstract

ABSTRACTIntroductionAs a mid-size international pharmaceutical company, we initiated 4 years ago the launch of a dedicated high-throughput computing platform supporting drug discovery. The platform named ‘Patrimony’was built up on the initial predicate to capitalize on our proprietary data while leveraging public data sources in order to foster a Computational Precision Medicine approach with the power of artificial intelligence.Areas coveredSpecifically, Patrimonyis designed to identify novel therapeutic target candidates. With several successful use cases in immuno-inflammatory diseases, and current ongoing extension to applications to oncology and neurology, we document how this industrial computational platform has had a transformational impact on our R&D, making it more competitive, as well time and cost effective through a model-based educated selection of therapeutic targets and drug candidates.Expert opinionWe report our achievements, but also our challenges in implementing data access and governance processes, building up hardware and user interfaces, and acculturing scientists to use predictive models to inform decisions.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results